These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 392183)
1. Role of parathyroid hormone in the pathogenesis of the uremic manifestations. Massry SG Klin Wochenschr; 1979 Oct; 57(19):1085-8. PubMed ID: 392183 [TBL] [Abstract][Full Text] [Related]
2. The search for uremic toxin(s) "X" "X" = PTH. Massry SG; Goldstein DA Clin Nephrol; 1979 Apr; 11(4):181-9. PubMed ID: 572276 [No Abstract] [Full Text] [Related]
3. [Parathormone as a uremic toxin. Physiopathological bases and general therapeutic guidelines]. Brancaccio D; Galmozzi C; Pizzocaro G Minerva Med; 1985 Mar; 76(9-10):377-82. PubMed ID: 3982693 [No Abstract] [Full Text] [Related]
4. Pathogenesis of uremic osteodystrophy. Agus ZS; Goldberg M Radiol Clin North Am; 1972 Dec; 10(3):545-56. PubMed ID: 4566892 [No Abstract] [Full Text] [Related]
5. Pathogenesis of the anemia of uremia: role of secondary hyperparathyroidism. Massry SG Kidney Int Suppl; 1983 Dec; 16():S204-7. PubMed ID: 6376915 [TBL] [Abstract][Full Text] [Related]
6. Role of parathyroid hormone in uremic toxicity. Massry SG; Goldstein DA Kidney Int Suppl; 1978 Jun; (8):S39-42. PubMed ID: 278896 [No Abstract] [Full Text] [Related]
7. Uremic Toxicity and Bone in CKD. Yamamoto S; Fukagawa M J Nephrol; 2017 Oct; 30(5):623-627. PubMed ID: 28573386 [TBL] [Abstract][Full Text] [Related]
8. Adynamic bone disease is a predominant bone pattern in early stages of chronic kidney disease. Massy Z; Drueke T J Nephrol; 2017 Oct; 30(5):629-634. PubMed ID: 28405928 [TBL] [Abstract][Full Text] [Related]
9. Role of uremic toxins in exacerbating anemia in renal failure. Macdougall IC Kidney Int Suppl; 2001 Feb; 78():S67-72. PubMed ID: 11168986 [TBL] [Abstract][Full Text] [Related]
10. ADAM17, a New Player in the Pathogenesis of Chronic Kidney Disease-Mineral and Bone Disorder. Perna AF; Pizza A; Di Nunzio A; Bellantone R; Raffaelli M; Cicchella T; Conzo G; Santini L; Zacchia M; Trepiccione F; Ingrosso D J Ren Nutr; 2017 Nov; 27(6):453-457. PubMed ID: 29056164 [TBL] [Abstract][Full Text] [Related]
12. Calcitriol may directly suppress bone turnover. Ureña P; Prieur P; Pétrover M Nephron; 1997; 75(1):116-7. PubMed ID: 9031288 [No Abstract] [Full Text] [Related]
13. Toxicity of parathyroid hormone in uremia. Klahr S; Slatopolsky E Annu Rev Med; 1986; 37():71-8. PubMed ID: 3010810 [TBL] [Abstract][Full Text] [Related]
14. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. Brandi L Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159 [TBL] [Abstract][Full Text] [Related]
15. Severe hyperparathyroidism with bone abnormalities and metastatic calcification in rats with adenine-induced uraemia. Tamagaki K; Yuan Q; Ohkawa H; Imazeki I; Moriguchi Y; Imai N; Sasaki S; Takeda K; Fukagawa M Nephrol Dial Transplant; 2006 Mar; 21(3):651-9. PubMed ID: 16311258 [TBL] [Abstract][Full Text] [Related]
16. Skeletal resistance to parathyroid hormone as a background abnormality in uremia. Fukagawa M; Iwasaki Y; Kazama JJ Nephrology (Carlton); 2003 Oct; 8 Suppl():S50-2. PubMed ID: 15012692 [TBL] [Abstract][Full Text] [Related]
18. Search for the uremic toxin. Decreased motor-nerve conduction velocity and elevated parathyroid hormone in uremia. Avram MM; Feinfeld DA; Huatuco AH N Engl J Med; 1978 May; 298(18):1000-3. PubMed ID: 205786 [TBL] [Abstract][Full Text] [Related]
19. Role of aluminum in uremic osteodystrophy. Luciani L; Rovelli E; Colleoni N; Mocetti P; Ballanti P; Bonucci E; D'Amico G Contrib Nephrol; 1990; 77():168-76. PubMed ID: 2188785 [No Abstract] [Full Text] [Related]
20. Parathyroid function in uremic children with and without osteodystrophy. Roof BS; Piel CF; Rames L; Potter D; Gordan GS Pediatrics; 1974 Mar; 53(3):404-9. PubMed ID: 4815261 [No Abstract] [Full Text] [Related] [Next] [New Search]